Edwards Lifesciences Corp — Director's Dealing 2021

May 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edwards Lifesciences Corp (EW)
CIK: 0001099800
Period of Report: 2021-05-24

Reporting Person: MUSSALLEM MICHAEL A (Director, Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-24	Common Stock	M	33000.0000	$21.7600	Acquired	221001.8200	Direct
2021-05-24	Common Stock	S	6623.0000	$96.1300	Disposed	214378.8200	Direct
2021-05-24	Common Stock	S	26377.0000	$95.5500	Disposed	188001.8200	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-24	Employee Stock Option (Right to Acquire)	$21.7600	M	33000.0000	Disposed	2022-05-13	Common Stock (33000.0000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	371728.8872	Indirect
Common Stock	3147787.0000	Indirect

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 3, 2020.

F2: This transaction was executed in multiple trades at prices ranging from $95.9400 to $96.4250. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $94.9200 to $95.9200. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

F4: Reflects shares represented on the most recent statement of the Issuer's 401(k) Plan Administrator.